Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson Progress
0% Complete
Foundational Principles of Intracerebral Hemorrhage

Foundational Principles of Intracerebral Hemorrhage

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Objective

Describe the foundational principles of intracerebral hemorrhage (ICH), including epidemiology, risk factors, pathophysiology, and clinical presentation.

1. Epidemiology of Intracerebral Hemorrhage

ICH is less common than ischemic stroke but carries a disproportionate burden of mortality and disability. Understanding incidence, outcomes, and population‐based risk factors informs resource allocation and early recognition strategies.

Incidence and Prevalence

  • Global incidence: 10–30 cases per 100,000 person-years
  • Higher rates in low- and middle-income countries; stable or rising trends in aging populations

Mortality and Morbidity

  • 30-day case fatality ≈40% among contemporary cohorts
  • Only 15–25% of survivors achieve functional independence at 6 months

Demographic Risk Factors

  • Age: risk doubles each decade after 55 years
  • Sex: male predominance with narrowing gap in older age
  • Ethnicity: higher incidence in Asian, Black, and Hispanic populations
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearl

ICH accounts for ~10% of strokes but contributes >50% of stroke‐related mortality.

2. Risk Factors for ICH

ICH risk arises from immutable factors (age, genetics, vessel pathology) and modifiable exposures (hypertension, antithrombotic use, lifestyle). Pharmacists play a critical role in identifying and mitigating modifiable risks.

Non-modifiable Risk Factors

  • Advanced age (>55 years)
  • Genetic predisposition: APOE ε2/ε4 genotype, cerebral amyloid angiopathy (CAA)
  • Vascular malformations: arteriovenous malformations, cavernomas

Modifiable Risk Factors

  • Chronic hypertension: leading risk for deep (basal ganglia, thalamus) hemorrhages
  • Anticoagulants: warfarin (INR >3), DOACs; antiplatelet agents carry smaller risk
  • Illicit drugs: cocaine, amphetamines
  • Lifestyle: heavy alcohol use, smoking, diabetes, hyperlipidemia

Pharmacist’s Role in Risk Mitigation

  • Comprehensive medication reconciliation to identify antithrombotics and interacting agents
  • Protocols for blood pressure monitoring and escalation
  • Patient education on adherence to antihypertensive therapy and warning signs of ICH
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearl

Uncontrolled hypertension and supratherapeutic anticoagulation are the most actionable drivers of ICH risk.

3. Pathophysiology of ICH

ICH begins with rupture of small cerebral vessels, leading to hematoma formation, mass effect, expansion, perihematomal edema, and secondary injury cascades. Each phase offers potential intervention targets.

Figure 1: Pathophysiological Cascade of Intracerebral Hemorrhage
Flowchart illustrating the progression of ICH: Vessel Rupture, Hematoma Formation & Expansion, Perihematomal Edema, and Secondary Brain Injury.
1. Vessel Rupture
Lipohyalinosis (Hypertension)
Cerebral Amyloid Angiopathy
Vascular Malformations
2. Hematoma Formation & Expansion
Primary Bleed & Mass Effect
Early Expansion (~30%)
CT “Spot Sign” (Active Bleed)
3. Perihematomal Edema & Inflammation
Cytotoxic Edema (hours)
Vasogenic Edema (days 3-5)
Inflammatory Mediators
4. Secondary Brain Injury Pathways
Excitotoxicity
Oxidative Stress
Apoptosis/Necrosis

Vessel Rupture Mechanisms

  • Lipohyalinosis from chronic hypertension weakens deep perforating arterioles
  • Amyloid β deposition in cortical vessels causes lobar hemorrhages (CAA)
  • Structural defects in vascular malformations predispose to bleeding

Hematoma Formation and Expansion

  • Primary bleed creates focal mass effect and raised intracranial pressure
  • Early hematoma expansion occurs in ~30% of patients within 24 hours
  • CT “spot sign” predicts active bleeding and risk of growth

Perihematomal Edema and Inflammation

  • Cytotoxic edema (hours): ionic shifts cause intracellular swelling
  • Vasogenic edema (peaks days 3–5): blood–brain barrier disruption allows plasma leakage
  • Inflammatory mediator release and microglial activation exacerbate tissue injury

Secondary Brain Injury Pathways

  • Excitotoxicity: glutamate release, calcium influx
  • Oxidative stress: free radical formation from blood breakdown products
  • Cell death via apoptosis and necrosis pathways
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearl

Early blood pressure control and rapid reversal of coagulopathy are the only proven measures to limit hematoma expansion.

4. Clinical Presentation of ICH

Clinical features depend on hemorrhage location and size. Prompt recognition of focal deficits, headache, altered consciousness, and signs of elevated intracranial pressure guides emergent imaging and triage.

Focal Neurological Deficits

  • Deep ICH (basal ganglia/thalamus): contralateral hemiparesis, sensory loss
  • Lobar ICH: aphasia, visual field deficits, hemispatial neglect
  • Cerebellar: ataxia, dysarthria, vertigo; brainstem: cranial nerve palsies, rapid decline

Headache and Pain Patterns

  • Sudden, severe headache (“worst of life”) more common in lobar and cerebellar bleeds
  • Nausea/vomiting often accompany raised intracranial pressure
  • Differentiation from SAH: focal deficits favor ICH; SAH more diffuse headache without focal signs

Altered Level of Consciousness

  • Glasgow Coma Scale quantifies impairment; lower scores correlate with larger hemorrhages
  • Fluctuations may indicate ongoing bleeding or rising ICP

Signs of Elevated Intracranial Pressure

  • Cushing triad: hypertension, bradycardia, irregular respiration
  • Pupillary asymmetry or sluggish reaction; posturing indicates impending herniation
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearl

Noncontrast CT is the diagnostic cornerstone; pharmacists should anticipate urgent needs for reversal agents and antihypertensives upon imaging confirmation.

References

  1. Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2022;53(7):e282–e361.
  2. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032–2060.
  3. Cook AM, Jones GM, Hawryluk GWJ, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care. 2020;32(3):647–666.
  4. Kernan WN, Ovbiagele B, Black HR, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and TIA. Stroke. 2021;52(7):e364–e467.